Evotec Says Sandoz Deal Is ‘Validation’ Of Biologics Ambitions
Chief Business Officer Matthias Evers Talks Biologics Technology Platform And Access
In the aftermath of announcing a major collaboration with Sandoz on biosimilars, Evotec’s chief business officer Matthias Evers speaks to Generics Bulletin about how the deal provides “validation” of Just-Evotec’s technology platform, while also outlining the firm’s wider ambitions to enable more efficient development of and broader access to biologics.
